DK2379598T3 - Anti-kir3d-antistoffer - Google Patents

Anti-kir3d-antistoffer Download PDF

Info

Publication number
DK2379598T3
DK2379598T3 DK10701221.3T DK10701221T DK2379598T3 DK 2379598 T3 DK2379598 T3 DK 2379598T3 DK 10701221 T DK10701221 T DK 10701221T DK 2379598 T3 DK2379598 T3 DK 2379598T3
Authority
DK
Denmark
Prior art keywords
antibody
cells
antibodies
kir3dl2
ser
Prior art date
Application number
DK10701221.3T
Other languages
English (en)
Inventor
Nicolas Anfossi
Laurent Gauthier
Yannis Morel
Alessandro Moretta
Silvia Parolini
Benjamin Rossi
Original Assignee
Innate Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innate Pharma filed Critical Innate Pharma
Application granted granted Critical
Publication of DK2379598T3 publication Critical patent/DK2379598T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Roof Covering Using Slabs Or Stiff Sheets (AREA)

Claims (15)

1. Isoleret antistof, der binder specifikt til en epitope i KIR3DL2-domæne 0 med aminosyresekvensen ifølge SEQ ID NO: 21, hvor antistoffet hæmmer proliferation af KIR3DL-udtrykkende, humane CD4+ T-lymfocytter i fravær af effektorceller og omfatter et konstant område af human IgG-isotype.
2. Antistof ifølge krav 1, hvor epitopen er en fælles determinant, der deles af KIR3DL1- og KIR3DL2-polypeptider.
3. Antistof ifølge krav 1 til 2, hvor antistoffet omfatter et modificeret Fc-domæne.
4. Antistof ifølge krav 3, hvor det modificerede Fc-domæne er hypofucosyleret.
5. Antistof ifølge et hvilket som helst af ovennævnte krav, hvor antistoffet konkurrerer om binding til KIR3DL2 med det bivalente antistof, der omfatter et variabelt område af tung kæde ifølge SEQ ID NO: 8 og et variabelt område af let kæde ifølge SEQ ID NO: 10.
6. Antistof ifølge et hvilket som helst af ovennævnte krav, hvor antistoffet er bivalent.
7. Antistof ifølge et hvilket som helst af ovennævnte krav, hvor antistoffet omfatter en tung kæde, der omfatter de tre CDR'er ifølge SEQ ID NO: 11 til 13, og en let kæde, der omfatter de tre CDR'er ifølge SEQ ID NO: 14 til 16.
8. Antistof ifølge et hvilket som helst af ovennævnte krav, hvor antistoffet et et humaniseret antistof eller et kimært antistof.
9. Monoklonalt antistof ifølge krav 1, der omfatter: (a) en tung kæde, der omfatter aminosyresekvensen ifølge SEQ ID NO: 8, der er fusioneret til et konstant område af en human IgGl-kæde; og (b) en let kæde, der omfatter aminosyresekvensen ifølge SEQ ID NO: 10, der er fusioneret til et konstant område af en human kappa-kæde.
10. Antistofsammensætning, der omfatter et antal antistoffer ifølge et hvilket som helst af ovennævnte krav, hvor mindst 40 % af antistofferne har en fælles N-koblet oligosaccharidstruktur af en biantennar type, der omfatter lange kæder med en terminal GlcNac, der er stærkt galactosyleret og ikke-fucosyleret.
11. Rekombinant værtscelle, der danner et antistof ifølge krav 1.
12. Værtscelle ifølge krav 11, hvor cellen er en aviær embryoafledt stamcellelinje.
13. Farmaceutisk præparat, der omfatter et antistof ifølge et hvilket som helst af kravene 1-10; og et farmaceutisk acceptabelt bæremateriale eller excipiens.
14. Præparat ifølge krav 13 til anvendelse som et medikament til modulering af T-celleaktivitet hos en patient, der lider af en autoimmunforstyrrelse, en inflammatorisk forstyrrelse eller en T-cellemalignitet.
15. Præparat til anvendelse ifølge krav 14, hvor forstyrrelsen er udvalgt fra gruppen, der består af arthritis, rheumatoid arthritis, spondylarthritis, Sezarys syndrom og mycosis fungoides.
DK10701221.3T 2009-01-19 2010-01-15 Anti-kir3d-antistoffer DK2379598T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14563509P 2009-01-19 2009-01-19
PCT/EP2010/050480 WO2010081890A1 (en) 2009-01-19 2010-01-15 Anti-kir3d antibodies

Publications (1)

Publication Number Publication Date
DK2379598T3 true DK2379598T3 (da) 2015-06-15

Family

ID=41796416

Family Applications (1)

Application Number Title Priority Date Filing Date
DK10701221.3T DK2379598T3 (da) 2009-01-19 2010-01-15 Anti-kir3d-antistoffer

Country Status (5)

Country Link
US (3) US9181341B2 (da)
EP (1) EP2379598B1 (da)
DK (1) DK2379598T3 (da)
ES (1) ES2539045T3 (da)
WO (1) WO2010081890A1 (da)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9447185B2 (en) 2005-10-14 2016-09-20 Innate Pharma, S.A. Compositions and methods for treating proliferative disorders
DE202007006021U1 (de) * 2007-04-19 2007-07-19 Conergy Ag Verbindbare Montageprofilschiene (Grundschiene)
US9175880B2 (en) 2010-12-10 2015-11-03 Solar Clam-P, Llc Panel clamping and mounting mechanism
US20160305459A1 (en) 2010-12-10 2016-10-20 Solar Clam-P Panel Mounting System and Method
JP6507097B2 (ja) * 2012-09-19 2019-04-24 イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． Ｋｉｒ３ｄｌ２結合剤
US10246510B2 (en) 2012-09-19 2019-04-02 Innate Pharma KIR3DL2 binding agents
WO2014124267A1 (en) * 2013-02-07 2014-08-14 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Method for diagnosis, prognosis and determination of treatment for cutaneous t-cell lymphoma
DK2958941T3 (da) 2013-02-20 2019-06-24 Innate Pharma Forbindelse, der binder specifikt til kir3dl2, til anvendelse til behandling af perifert t-cellelymfom
US20160045594A1 (en) * 2013-03-27 2016-02-18 Fred Hutchinson Cancer Research Center Directed immune stimulation
US20160130346A1 (en) * 2013-05-29 2016-05-12 Institut National De La Sante Et De La Recherche Medicale Kir3dl2 is a biomarker and a therapeutic target useful for respectively preventing and treating a subset of cutaneous and non-cutaneous peripheral t-cell lymphomas
US9231518B2 (en) * 2013-10-21 2016-01-05 Spice Solar, Inc. Solar panel mechanical connector and frame
SG11201606789SA (en) * 2014-03-14 2016-09-29 Innate Pharma Humanized antibodies with increased stability
US9853593B2 (en) * 2014-07-07 2017-12-26 Spice Solar, Inc. Solar panel mechanical connector and frame
WO2016030488A1 (en) 2014-08-27 2016-03-03 Innate Pharma Treatment of celiac disease
USD825951S1 (en) * 2016-06-16 2018-08-21 Walmart Apollo, Llc Retail store fixture
JP2020500161A (ja) 2016-10-21 2020-01-09 イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． 抗ｋｉｒ３ｄｌ２剤による処置
CA3052291A1 (en) 2017-02-09 2018-08-16 Memorial Sloan Kettering Cancer Center Anti-kir3dl1 antibodies
WO2020152081A1 (en) 2019-01-22 2020-07-30 Innate Pharma Treatment of t cell lymphoma
US11223320B2 (en) * 2019-03-12 2022-01-11 Chandramouli Vaidyanathan Solar panel flat roof mounting apparatus and method
AU2022255908A1 (en) 2021-04-05 2023-10-05 Innate Pharma Immunohistochemistry methods and kir3dl2-specific reagents
US11757400B1 (en) 2023-03-15 2023-09-12 Sunmodo Corporation Devices for mounting solar PV panels to roofs and other mounting structures

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3100556A (en) * 1959-07-30 1963-08-13 Reynolds Metals Co Interlocking metallic structural members
US3210808A (en) * 1964-02-06 1965-10-12 Creager Billy Neal Flexible mullion
US3381437A (en) * 1964-04-21 1968-05-07 Bruce W. Kidney Slip spline suspended ceiling structure
US4308858A (en) * 1979-10-29 1982-01-05 Skillman Dale N Solar energy collecting apparatus and methods
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
DK0605522T3 (da) 1991-09-23 2000-01-17 Medical Res Council Fremgangsmåde til fremstilling af humaniserede antistoffer
US5660827A (en) 1992-03-05 1997-08-26 Board Of Regents, The University Of Texas System Antibodies that bind to endoglin
US5340740A (en) 1992-05-15 1994-08-23 North Carolina State University Method of producing an avian embryonic stem cell culture and the avian embryonic stem cell culture produced by the process
US5617677A (en) * 1992-08-20 1997-04-08 Hallsten Corporation Tank or channel cover
DE614989T1 (de) 1993-02-17 1995-09-28 Morphosys Proteinoptimierung Verfahren für in vivo Selektion von Ligandenbindende Proteine.
NL9301551A (nl) * 1993-05-07 1994-12-01 Hendrikus Johannes Schijf Paneel, alsmede scharnierprofiel, dat onder meer geschikt is voor een dergelijk paneel.
FR2726003B1 (fr) 1994-10-21 2002-10-18 Agronomique Inst Nat Rech Milieu de culture de cellules embryonnaires totipotentes aviaires, procede de culture de ces cellules, et cellules embryonnaires totipotentes aviaires
FR2749021B1 (fr) 1996-05-23 2001-10-26 Agronomique Inst Nat Rech Lignees de cellules aviaires immortalisees
CA2288992C (en) 1997-04-30 2012-06-12 Enzon, Inc. Single-chain antigen-binding proteins capable of glycosylation, production and uses thereof
EP2261229A3 (en) 1998-04-20 2011-03-23 GlycArt Biotechnology AG Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
DE60037107T2 (de) 1999-02-11 2008-09-25 Hanmi Pharm. Co., Ltd. Pluripotente embryonale keimzellinie aus vögeln
ES2568899T3 (es) 1999-04-09 2016-05-05 Kyowa Hakko Kirin Co., Ltd. Procedimiento para controlar la actividad de una molécula inmunofuncional
US6374552B1 (en) * 2000-04-12 2002-04-23 Alliance Concrete Concepts, Inc. Skirting wall system
US7207147B2 (en) * 2000-09-20 2007-04-24 Alliance Concrete Concepts, Inc. Mortarless wall structure
CA2314789C (en) * 2000-07-31 2006-06-20 Royal Group Technologies Limited T-mullion
ATE556092T1 (de) * 2000-12-18 2012-05-15 Inst Nat Sante Rech Med Mittel zur diagnose und therapie von ctcl
US6557955B2 (en) * 2001-01-13 2003-05-06 Darren Saravis Snap together modular storage
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
WO2002074969A2 (en) 2001-01-26 2002-09-26 University Of Lausanne Matrix attachment regions and methods for use thereof
EP1406472A1 (en) 2001-07-09 2004-04-07 Ibiden Co., Ltd. Ceramic heater and ceramic joined article
US20030157108A1 (en) 2001-10-25 2003-08-21 Genentech, Inc. Glycoprotein compositions
FR2836924B1 (fr) 2002-03-08 2005-01-14 Vivalis Lignees de cellules aviaires utiles pour la production de substances d'interet
US20040110704A1 (en) 2002-04-09 2004-06-10 Kyowa Hakko Kogyo Co., Ltd. Cells of which genome is modified
IL151244A (en) * 2002-08-14 2006-10-31 Chagim Nechalim Ind Ltd Panel for modular construction
US7082727B2 (en) * 2003-05-16 2006-08-01 Industries Covers Inc. Hung window with snap-fit assembly
ATE467678T1 (de) 2003-07-22 2010-05-15 Vivalis Produktion von poxviren mit adhärenten oder nicht adhärenten vogelzellinien
CN1863913B (zh) 2003-10-24 2011-01-12 思兰克斯有限公司 通过mar序列的多次转染过程在哺乳动物细胞中实现高效基因转移和表达
JP2007534631A (ja) 2003-10-28 2007-11-29 ノボ　ノルディスク　アクティーゼルスカブ ラミニン−５γ２結合性ペプチド、その関連組成物およびその使用
AU2006255085A1 (en) 2005-06-03 2006-12-14 Genentech, Inc. Method of producing antibodies with modified fucosylation level
US9447185B2 (en) * 2005-10-14 2016-09-20 Innate Pharma, S.A. Compositions and methods for treating proliferative disorders
JP4684874B2 (ja) * 2005-12-13 2011-05-18 株式会社屋根技術研究所 太陽電池モジュール枠体
MX2008009221A (es) 2006-01-17 2008-11-27 Biolex Therapeutics Inc Composiciones y metodos para la humanizacion y optimizacion de n-glicanos en plantas.
EP1878747A1 (en) 2006-07-11 2008-01-16 greenovation Biotech GmbH Glyco-engineered antibodies
EP1985305A1 (en) 2007-04-24 2008-10-29 Vivalis Duck embryonic derived stem cell lines for the production of viral vaccines
EP1995309A1 (en) 2007-05-21 2008-11-26 Vivalis Recombinant protein production in avian EBx® cells
JP4290750B2 (ja) * 2007-06-11 2009-07-08 株式会社屋根技術研究所 太陽電池モジュールの固定構造、太陽電池モジュール用のフレーム及び固定部材
US7690719B2 (en) * 2007-07-17 2010-04-06 Monaco Coach Corporation Articulating interlocking structural extrusions for recreational vehicles and the like
CA2741489A1 (en) * 2008-10-22 2010-04-29 The Regents Of The University Of Michigan Methods, compositions, and kits for diagnosing, monitoring, and treating disease
JP6507097B2 (ja) * 2012-09-19 2019-04-24 イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． Ｋｉｒ３ｄｌ２結合剤

Also Published As

Publication number Publication date
WO2010081890A1 (en) 2010-07-22
US20160046713A1 (en) 2016-02-18
US20120064081A1 (en) 2012-03-15
US9181341B2 (en) 2015-11-10
EP2379598B1 (en) 2015-03-11
EP2379598A1 (en) 2011-10-26
ES2539045T3 (es) 2015-06-25
US20100206301A1 (en) 2010-08-19
US9828427B2 (en) 2017-11-28

Similar Documents

Publication Publication Date Title
DK2379598T3 (da) Anti-kir3d-antistoffer
US11919970B2 (en) Antibodies and chimeric antigen receptors specific for ROR1
US11858990B2 (en) KIR3DL2 binding agents
US11466087B2 (en) Anti-CLL-1 antibodies and methods of use
RU2741105C2 (ru) Антитела и химерные антигенные рецепторы, специфичные к cd19
EP4112644A1 (en) Anti-lag3 antibodies
JP6405242B2 (ja) Ｍｉｃａ結合剤
JP2020527144A (ja) 癌を処置するためのヒトｓｉｇｌｅｃ−９に対する抗体およびヒトｎｋｇ２ａに対する抗体を使用する組み合わせ療法
KR20210104079A (ko) 항-trem2 항체를 사용하는 방법
JP2019502690A (ja) 抗ｃｄ３０３膜貫通タンパク質抗体の新たな使用